Certain graphics on this page may be affected by ad-blocking software. If portions of the page appear blank and an ad blocker is enabled, please disable the ad blocker and refresh the page to ensure ...
Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback